Literature DB >> 20832407

Impaired immune responses following spinal cord injury lead to reduced ability to control viral infection.

Katherine S Held1, Oswald Steward, Caroline Blanc, Thomas E Lane.   

Abstract

Spinal cord injuries disrupt central autonomic pathways that regulate immune function, and increasing evidence suggests that this may cause deficiencies in immune responses in people with spinal cord injuries. Here we analyze the consequences of spinal cord injury (SCI) on immune responses following experimental viral infection of mice. Female C57BL/6 mice received complete crush injuries at either thoracic level 3 (T3) or 9 (T9), and 1 week post-injury, injured mice and un-injured controls were infected with different dosages of mouse hepatitis virus (MHV, a positive-strand RNA virus). Following MHV infection, T3- and T9-injured mice exhibited increased mortality in comparison to un-injured and laminectomy controls. Infection at all dosages resulted in significantly higher viral titer in both T3- and T9-injured mice compared to un-injured controls. Investigation of anti-viral immune responses revealed impairment of cellular infiltration and effector functions in mice with SCI. Specifically, cell-mediated responses were diminished in T3-injured mice, as seen by reduction in virus-specific CD4(+) T lymphocyte proliferation and IFN-γ production and decreased numbers of activated antigen presenting cells compared to infected un-injured mice. Collectively, these data indicate that the inability to control viral replication following SCI is not level dependent and that increased susceptibility to infection is due to suppression of both innate and adaptive immune responses.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20832407      PMCID: PMC5029284          DOI: 10.1016/j.expneurol.2010.08.036

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  40 in total

Review 1.  Neural immunoregulation: emerging roles for nerves in immune homeostasis and disease.

Authors:  J E Downing; J A Miyan
Journal:  Immunol Today       Date:  2000-06

Review 2.  Central nervous system injury-induced immune deficiency syndrome.

Authors:  Christian Meisel; Jan M Schwab; Konstantin Prass; Andreas Meisel; Ulrich Dirnagl
Journal:  Nat Rev Neurosci       Date:  2005-10       Impact factor: 34.870

3.  Changes in the density and distribution of sympathetic nerves in spleens from Lewis rats with adjuvant-induced arthritis suggest that an injury and sprouting response occurs.

Authors:  Dianne Lorton; Cheri Lubahn; Carl A Lindquist; Jill Schaller; Cathy Washington; Denise L Bellinger
Journal:  J Comp Neurol       Date:  2005-08-22       Impact factor: 3.215

4.  Mice lacking IL-12 develop polarized Th1 cells during viral infection.

Authors:  V E Schijns; B L Haagmans; C M Wierda; B Kruithof; I A Heijnen; G Alber; M C Horzinek
Journal:  J Immunol       Date:  1998-04-15       Impact factor: 5.422

5.  Utility of mouse cell line DBT for propagation and assay of mouse hepatitis virus.

Authors:  N Hirano; T Murakami; K Fujiwara; M Matsumoto
Journal:  Jpn J Exp Med       Date:  1978-02

6.  Characterization of the central nervous system innervation of the rat spleen using viral transneuronal tracing.

Authors:  G Cano; A F Sved; L Rinaman; B S Rabin; J P Card
Journal:  J Comp Neurol       Date:  2001-10-08       Impact factor: 3.215

7.  Evidence for differential roles for NKG2D receptor signaling in innate host defense against coronavirus-induced neurological and liver disease.

Authors:  Kevin B Walsh; Melissa B Lodoen; Robert A Edwards; Lewis L Lanier; Thomas E Lane
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

8.  Mouse hepatitis virus liver pathology is dependent on ADP-ribose-1''-phosphatase, a viral function conserved in the alpha-like supergroup.

Authors:  Klara Kristin Eriksson; Luisa Cervantes-Barragán; Burkhard Ludewig; Volker Thiel
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

9.  CXC chemokine ligand 10 controls viral infection in the central nervous system: evidence for a role in innate immune response through recruitment and activation of natural killer cells.

Authors:  Matthew J Trifilo; Cynthia Montalto-Morrison; Linda N Stiles; Kelley R Hurst; Jenny L Hardison; Jerry E Manning; Paul S Masters; Thomas E Lane
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  CD8+ T-cell epitopes within the surface glycoprotein of a neurotropic coronavirus and correlation with pathogenicity.

Authors:  R F Castro; S Perlman
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

View more
  23 in total

Review 1.  Immune dysfunction and chronic inflammation following spinal cord injury.

Authors:  D J Allison; D S Ditor
Journal:  Spinal Cord       Date:  2014-11-04       Impact factor: 2.772

2.  Additive effects of exogenous IL-12 supplementation and antibiotic treatment in infection prophylaxis.

Authors:  Brandon M Boyce; Brock A Lindsey; Nina B Clovis; E Suzanne Smith; Gerald R Hobbs; David F Hubbard; Sanford E Emery; John B Barnett; Bingyun Li
Journal:  J Orthop Res       Date:  2011-08-03       Impact factor: 3.494

3.  Spinal cord injury-induced immune deficiency syndrome enhances infection susceptibility dependent on lesion level.

Authors:  Benedikt Brommer; Odilo Engel; Marcel A Kopp; Ralf Watzlawick; Susanne Müller; Harald Prüss; Yuying Chen; Michael J DeVivo; Felix W Finkenstaedt; Ulrich Dirnagl; Thomas Liebscher; Andreas Meisel; Jan M Schwab
Journal:  Brain       Date:  2016-01-10       Impact factor: 13.501

4.  Long-term functional outcome in patients with acquired infections after acute spinal cord injury.

Authors:  Marcel A Kopp; Ralf Watzlawick; Peter Martus; Vieri Failli; Felix W Finkenstaedt; Yuying Chen; Michael J DeVivo; Ulrich Dirnagl; Jan M Schwab
Journal:  Neurology       Date:  2017-01-27       Impact factor: 9.910

5.  Chronic spinal cord injury impairs primary antibody responses but spares existing humoral immunity in mice.

Authors:  Michael A Oropallo; Katherine S Held; Radhika Goenka; Sifat A Ahmad; Patrick J O'Neill; Oswald Steward; Thomas E Lane; Michael P Cancro
Journal:  J Immunol       Date:  2012-04-20       Impact factor: 5.422

6.  Supplementation With Vitamin E, Zinc, Selenium, and Copper Re-Establishes T-Cell Function and Improves Motor Recovery in a Rat Model of Spinal Cord Injury.

Authors:  Elisa Garcia; Fernanda Hernández-Ayvar; Roxana Rodríguez-Barrera; Adrián Flores-Romero; Cesar Borlongan; Antonio Ibarra
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.139

7.  Barriers to personal hygiene in persons with spinal cord injury during the COVID-19 pandemic and lockdown: A rehabilitation perspective of two cases.

Authors:  Raktim Swarnakar; Shreya Santra; S L Yadav
Journal:  J Family Med Prim Care       Date:  2022-05-14

8.  Spinal Cord Injury Suppresses Cutaneous Inflammation: Implications for Peripheral Wound Healing.

Authors:  Jessica M Marbourg; Anna Bratasz; Xiaokui Mo; Phillip G Popovich
Journal:  J Neurotrauma       Date:  2016-10-17       Impact factor: 5.269

Review 9.  Spinal cord injury, immunodepression, and antigenic challenge.

Authors:  Katherine S Held; Thomas E Lane
Journal:  Semin Immunol       Date:  2014-04-18       Impact factor: 11.130

10.  The SCIentinel study--prospective multicenter study to define the spinal cord injury-induced immune depression syndrome (SCI-IDS)--study protocol and interim feasibility data.

Authors:  Marcel A Kopp; Claudia Druschel; Christian Meisel; Thomas Liebscher; Erik Prilipp; Ralf Watzlawick; Paolo Cinelli; Andreas Niedeggen; Klaus-Dieter Schaser; Guido A Wanner; Armin Curt; Gertraut Lindemann; Natalia Nugaeva; Michael G Fehlings; Peter Vajkoczy; Mario Cabraja; Julius Dengler; Wolfgang Ertel; Axel Ekkernkamp; Peter Martus; Hans-Dieter Volk; Nadine Unterwalder; Uwe Kölsch; Benedikt Brommer; Rick C Hellmann; Ramin R Ossami Saidy; Ines Laginha; Harald Prüss; Vieri Failli; Ulrich Dirnagl; Jan M Schwab
Journal:  BMC Neurol       Date:  2013-11-09       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.